CN113286619A - 用于调节适应性免疫的组合物和方法 - Google Patents

用于调节适应性免疫的组合物和方法 Download PDF

Info

Publication number
CN113286619A
CN113286619A CN201980051039.7A CN201980051039A CN113286619A CN 113286619 A CN113286619 A CN 113286619A CN 201980051039 A CN201980051039 A CN 201980051039A CN 113286619 A CN113286619 A CN 113286619A
Authority
CN
China
Prior art keywords
sequence
rna
present disclosure
protein
grna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980051039.7A
Other languages
English (en)
Chinese (zh)
Inventor
D·A·内尔斯
R·巴特拉
E·杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rocana Biological Co ltd
Locana Inc
Original Assignee
Rocana Biological Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rocana Biological Co ltd filed Critical Rocana Biological Co ltd
Publication of CN113286619A publication Critical patent/CN113286619A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980051039.7A 2018-06-08 2019-06-07 用于调节适应性免疫的组合物和方法 Pending CN113286619A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682276P 2018-06-08 2018-06-08
US62/682,276 2018-06-08
PCT/US2019/036050 WO2019236998A1 (en) 2018-06-08 2019-06-07 Compositions and methods for the modulation of adaptive immunity

Publications (1)

Publication Number Publication Date
CN113286619A true CN113286619A (zh) 2021-08-20

Family

ID=68769461

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980051039.7A Pending CN113286619A (zh) 2018-06-08 2019-06-07 用于调节适应性免疫的组合物和方法

Country Status (9)

Country Link
US (2) US20190382759A1 (https=)
EP (1) EP3801641A4 (https=)
JP (1) JP2021526860A (https=)
KR (1) KR20210060429A (https=)
CN (1) CN113286619A (https=)
AU (1) AU2019281006A1 (https=)
CA (1) CA3102783A1 (https=)
SG (1) SG11202012015YA (https=)
WO (1) WO2019236998A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114720699A (zh) * 2022-04-22 2022-07-08 浙江大学 一种结直肠癌早期预警血清指标及其检测方法和应用
CN116019935A (zh) * 2022-06-22 2023-04-28 华中科技大学同济医学院附属同济医院 Ago2在制备治疗心衰或糖尿病性心肌病的药物方面的用途及其蛋白、基因、转化体
WO2023208256A1 (zh) * 2022-04-26 2023-11-02 北京干细胞与再生医学研究院 经分离的Cas13蛋白、基于它的基因编辑系统及其用途

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499805B2 (en) 2010-06-18 2016-11-22 The University Of North Carolina At Chapel Hill Methods and compositions for synthetic RNA endonucleases
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
JP2021526858A (ja) 2018-06-08 2021-10-11 ロックアネイビオ， インコーポレイテッド Ｒｎａ標的化融合タンパク質組成物および使用方法
AU2020208346B2 (en) 2019-01-14 2026-01-29 University Of Rochester Targeted nuclear RNA cleavage and polyadenylation with CRISPR-cas
WO2021011504A1 (en) * 2019-07-12 2021-01-21 Duke University Nanoparticle systems for targeted delivery of crispr/cas13 and methods of using same
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
CN113136376B (zh) * 2021-05-26 2022-10-21 武汉大学 一种Cas12a变体及其在基因编辑中的应用
WO2023150131A1 (en) * 2022-02-01 2023-08-10 The Regents Of The University Of California Method of regulating alternative polyadenylation in rna
CN114848808B (zh) * 2022-03-24 2023-04-25 四川大学 基于阳离子脂多肽及细胞因子的免疫增强剂及制法、应用
WO2024264035A2 (en) * 2023-06-22 2024-12-26 The General Hospital Corporation Compositions and methods of generating endogenous tdr molecules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170145394A1 (en) * 2015-11-23 2017-05-25 The Regents Of The University Of California Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
WO2017093969A1 (en) * 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12180499B2 (en) * 2016-10-31 2024-12-31 University Of Florida Research Foundation, Inc. Compositions and methods for impeding transcription of expanded microsatellite repeats
AU2018234825B2 (en) * 2017-03-15 2020-12-17 Massachusetts Institute Of Technology Novel CAS13B orthologues CRISPR enzymes and systems
US11168322B2 (en) * 2017-06-30 2021-11-09 Arbor Biotechnologies, Inc. CRISPR RNA targeting enzymes and systems and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170145394A1 (en) * 2015-11-23 2017-05-25 The Regents Of The University Of California Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
WO2017091630A1 (en) * 2015-11-23 2017-06-01 The Regents Of The University Of California Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
WO2017093969A1 (en) * 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAVID B.T. CO: "RNA Editing with CRISPR-Cas13", SCIENCE, vol. 258, no. 6366, pages 1019 - 1027, XP055491658, DOI: 10.1126/science.aaq0180 *
JIANGTAO REN: "Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition", CLINICAL CANCER RESEARCH, vol. 23, no. 9, 1 May 2017 (2017-05-01), pages 2255 - 226, XP055565027, DOI: 10.1158/1078-0432.CCR-16-1300 *
SILVANA KONERMANN: "Transcriptome engineering with RNA-targeting Type VI-D CRISPR effectors", CELL, vol. 173, no. 3, 19 April 2018 (2018-04-19), pages 665 - 676, XP055529705, DOI: 10.1016/j.cell.2018.02.033 *
汤锦波: "手部肌腱外科学", 31 January 2018, 山东科学技术出版社, pages: 64 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114720699A (zh) * 2022-04-22 2022-07-08 浙江大学 一种结直肠癌早期预警血清指标及其检测方法和应用
WO2023208256A1 (zh) * 2022-04-26 2023-11-02 北京干细胞与再生医学研究院 经分离的Cas13蛋白、基于它的基因编辑系统及其用途
CN116019935A (zh) * 2022-06-22 2023-04-28 华中科技大学同济医学院附属同济医院 Ago2在制备治疗心衰或糖尿病性心肌病的药物方面的用途及其蛋白、基因、转化体
CN116019935B (zh) * 2022-06-22 2025-01-17 华中科技大学同济医学院附属同济医院 Ago2在制备治疗心衰或糖尿病性心肌病的药物方面的用途及其蛋白、基因、转化体

Also Published As

Publication number Publication date
US20240344060A1 (en) 2024-10-17
EP3801641A1 (en) 2021-04-14
SG11202012015YA (en) 2021-01-28
WO2019236998A1 (en) 2019-12-12
US20190382759A1 (en) 2019-12-19
CA3102783A1 (en) 2019-12-12
JP2021526860A (ja) 2021-10-11
KR20210060429A (ko) 2021-05-26
EP3801641A4 (en) 2022-09-28
AU2019281006A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
CN113286619A (zh) 用于调节适应性免疫的组合物和方法
US10822617B2 (en) RNA-targeting fusion protein compositions and methods for use
CN114450031A (zh) 靶向rna的敲低和替代组合物及使用方法
AU2021236446B2 (en) CRISPR-Cas-related methods, compositions and components for cancer immunotherapy
US20220127621A1 (en) Fusion proteins and fusion ribonucleic acids for tracking and manipulating cellular rna
JP7379447B2 (ja) ゲノム編集分子の細胞内送達のためのペプチドおよびナノ粒子
JP2026016399A (ja) がん免疫療法のためのｃｒｉｓｐｒ－ｃｐｆ１関連方法、組成物および構成要素
CN110869498A (zh) 经由核递送crispr/cas9导向编辑细胞rna
US20220220473A1 (en) Protein translational control
CN112041436A (zh) 雷帕霉素抗性细胞
AU2019326617A1 (en) FASL immunomodulatory gene therapy compositions and methods for use
CN113423831A (zh) 核酸酶介导的重复扩增
WO2025227064A1 (en) Genomic editing methods to treat cardiovascular disease, and compositions for use in practicing the same
CN119421951A (zh) 用于c9orf72重复序列扩增疾病的crispr干扰疗法
HK40043159A (en) Rapamycin resistant cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210820